生物医药ETF（512290）盘中涨超2%，政策优化提振行业预期

Core Insights - The release of the 11th batch of national drug procurement documents includes 55 major products, optimizing requirements for participating companies, volume reporting, and rules, moving away from solely selecting based on low prices, which may mark an important turning point [1] - The highest effective bid price calculation excludes abnormally low prices from provincial-level procurement to avoid extreme pricing affecting overall pricing benchmarks, and companies are required to commit to pricing not lower than their costs [1] - Higher quality standards for drugs are mandated, including a requirement for bidding companies to have at least two years of production experience for similar dosage forms and no GMP violations in the past two years [1] - The Shanghai municipal government has issued an action plan to promote the full-chain development of high-end medical device industries, with 20 key tasks aimed at innovation, clinical empowerment, and regulatory approval, planning to add over 500 domestic Class III medical device registration certificates by 2027 and cultivate leading enterprises with an annual output value exceeding 10 billion [1] - Industry policies are gradually being implemented this year, promoting stabilization and recovery in the sector, benefiting the long-term healthy development of pharmaceuticals and medical devices [1] - The Biopharmaceutical ETF (512290) tracks the CS Biomedicine Index (930726), which selects listed companies in biotechnology, healthcare equipment, and services to reflect the overall performance of biopharmaceutical-related securities [1] - The CS Biomedicine Index constituents exhibit high growth and innovation, serving as an important indicator of the development trend in China's biopharmaceutical industry [1]